Strides Arcolab trades jubilantly on getting US FDA’s nod for Adenoscan Injection

25 Mar 2014 Evaluate

Strides Arcolab is currently trading at Rs. 382.10, up by 17.05 points or 4.67% from its previous closing of Rs. 365.05 on the BSE.

The scrip opened at Rs. 365.80 and has touched a high and low of Rs. 389.00 and Rs. 363.25 respectively. So far 267385 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1050.00 on 05-Dec-2013 and a 52 week low of Rs. 343.80 on 26-Feb-2014.

Last one week high and low of the scrip stood at Rs. 389.00 and Rs. 357.00 respectively. The current market cap of the company is Rs. 2173.55 crore.

The promoters holding in the company stood at 27.17% while Institutions and Non-Institutions held 52.29% and 20.54% respectively.

Strides Arcolab has received US Food and Drug Administration (US FDA) approval for Adenoscan Injection Generic. Astellas Pharma’s heart drug Adenoscan sales stood at $65 million per year. Teva pharma’s Adenoscan exclusivity has ended on March 23, 2014.

Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

846.75 -24.65 (-2.83%)
21-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.00
Dr. Reddys Lab 5780.70
Cipla 1442.00
Zydus Lifesciences 1088.45
Lupin 1683.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.